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PENYARINGAN MOLEKUL KECIL PERENCAT DEGRADASI p27
Kip1
  
 
ABSTRAK 
 
 Dalam majoriti kanser manusia, perencat “cyclin-dependent kinase” (CDK) yang 
dikenali sebagai p27
Kip1
, biasanya didapati didegradasikan secara aktif oleh laluan 
ubiquitin-proteasom yang terdiri daripada komponen SCF
Skp2
 E3 Ligase. Walaupun 
perencat proteasom bertindak untuk menstabilkan p27
Kip1
, molekul kecil perencat yang 
berkebolehan untuk merencatkan degradasi p27
Kip1
 oleh fungsi SCF
Skp2
 E3 Ligase 
seterusnya akan menyumbang kepada penghasilan ubat yang lebih spesifik dan efisien 
dengan kesan sampingan yang lebih rendah. Dalam kajian ini, satu sistem penyaringan 
daya pemprosesan tinggi berpandukan interaksi protein-protein yang bergantung kepada 
pemfosforilan dengan menggunakan sistem ekspresi protein baculovirus telah 
dibangunkan. Sistem ini telah meningkatkan daya pemprosesan untuk menyaringi 
perpustakaan sebatian kimia yang besar dalam Depositori Produk Semulajadi RIKEN 
(NPDepo) dan telah memudahkan pengenalpastian perencat molekul kecil degradasi 
p27
Kip1
. Dalam sistem ekspresi protein baculovirus, protein 2 berdasarkan-kinase fasa-S 
(Skp2) yang ditag dengan pendarfluor monomerik Azami Hijau (mAG) dan subunit 1 
CDK (Cks1) (mAGSkp2-Cks1) kompleks telah dihasilkan. Pengikatan kompleks 
mAGSkp2-Cks1 kepada p27
Kip1
 fosfopeptida berdasarkan pemfosforilan telah disahkan 
melalui spektrofluorometri. Dengan pendekatan ini, kira-kira 20,000 sebatian kimia 
dengan keberatan molekul yang rendah yang disimpan dalam RIKEN NPDepo telah 
disaringi dan dua sebatian molekul kecil iaitu linichlorin A and gentian violet telah 
dikenalpasti merencat interaksi antara mAGSkp2-Cks1 dan p27
Kip1
 fosfopeptida. Kajian 
 xiii 
yang lanjut menunjukkan bahawa sebatian-sebatian tersebut telah merencat 
“ubiquitination” p27Kip1 in vitro. Sebatian kecil tersebut juga didapati menstabilkan 
tahap p27
Kip1
 dalam sel HeLa yang seterusnya menghalang degradasi pesat p27
Kip1
. 
Kedua-dua sebatian itu juga menunjukkan aktiviti antiproliferatif yang lebih cenderung 
terhadap sel HeLa dan sel mencit terubahsuai, tsFT210 berbanding dengan fibroblast 
embrio mencit, sel NIH3T3 pada kepekatan 3.2 µM dan 1.6 µM untuk linichlorin A dan 
0.4 µM dan 0.6 µM untuk gentian violet masing-masing untuk sel HeLa dan sel tsFT210. 
Selain itu, sebatian-sebatian tersebut juga merangsang perlambatan kemajuan fasa G1 
dalam sel tsFT210 pada kepekatan yang sama. Pengenalpastian molekul kecil perencat 
yang spesifik dan pendekatan yang digunakan dalam kajian ini mencadangkan strategi 
yang berpotensi untuk restorasi tahap p27
Kip1
 protein dalam kanser manusia.     
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SCREENING FOR SMALL MOLECULE INHIBITORS OF p27
Kip1
 
DEGRADATION  
 
ABSTRACT 
 
In a majority of human cancers, the cyclin-dependent kinase (CDK) inhibitor 
p27
Kip1
 is commonly found to be deregulated due to proteolysis by the ubiquitin-
proteasome pathway involving the SCF
Skp2
 E3 ligase. Although proteasome inhibitors 
act to stabilize p27
Kip1
, small molecules agents inhibiting the degradation of p27
Kip1
 by 
the function of SCF
Skp2
 E3 ligase may contribute to the development of a specific 
targeted drug that could prove to be more efficacious with less side effects. In this work, 
we have developed a high-throughput screening system based on phosphorylation 
dependent protein-protein interaction using the baculovirus protein expression system. 
This system has provided an increased throughput in screening of large libraries of 
compounds in RIKEN Natural Products Depository (NPDepo) and has facilitated the 
identification of small molecule inhibitors of p27
Kip1
 degradation. In the baculovirus 
protein expression system, S-phase kinase-associated protein 2 (Skp2) tagged with 
fluorescent monomeric Azami Green (mAG) and CDK subunit 1 (Cks1) (mAGSkp2-
Cks1) complex was constructed. The binding of mAGSkp2-Cks1 complex to p27
Kip1
 
phosphopeptides in a phosphorylation dependent manner was confirmed by 
spectrofluorometry. With this approach, we have screened approximately 20,000 low 
molecular weight compounds stored in RIKEN NPDepo and have identified two small 
molecule compounds namely; linichlorin A and gentian violet that were shown to inhibit 
the interaction between mAGSkp2-Cks1 and p27
Kip1
 phosphopeptides. Further studies 
 xv 
have shown that the compounds inhibited the in vitro ubiquitination of p27
Kip1
. It was 
discovered that these small molecule compounds stabilized the level of p27
Kip1 
in HeLa 
cells, thus preventing the rapid degradation of p27
Kip1
. Both of the compounds exhibited 
preferential antiproliferative activity against HeLa cells and transformed mouse cells, 
tsFT210 relative to the mouse embryonic fibroblast, NIH3T3 cells at concentrations of 
3.2 µM and 1.6 µM for linichlorin A and 0.4 µM and 0.6 µM for gentian violet, 
respectively, in HeLa cells and tsFT210 cells. Moreover, the compounds also induced 
delay in the G1 phase progression using tsFT210 cells at the same concentrations. The 
identification of these specific small molecule inhibitors and the approaches taken in our 
study suggest a potential strategy for the restoration of p27
Kip1
 levels in human cancers.  
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CHAPTER ONE 
Introduction 
 
1.1 General Introduction 
The applications of chemical principles and techniques to biological systems 
have had remarkable advancements in the fields of chemistry and biology. This 
emerging multidiscipline approach, also known as chemical biology, has notably 
contributed in the elucidation of many important underlying biochemical structures and 
functions including proteins and DNA (Martin and Schultz, 1999). Indeed, the deeper 
understanding has enabled the manipulation of nucleic acid and protein in living 
organism, providing platforms in various applications such as proteomics, genetic 
engineering and pharmacology.  
 In the past few years, the approach of chemical biology has been extensively 
applied on many biological studies by the use of small molecule probes. These small 
molecules had been proven to be useful in exploring protein function and cell biology. 
Recently, high-throughput screening (HTS) has become a routine method used in many 
research laboratories in the effort to discover such small molecules in chemical biology 
studies. The flexibility and high-throughput speed of the HTS process have facilitated 
the rapid screening of small molecules for novel drug discovery (Inglese et al., 2007). 
Due to the higher molecular weight of natural compounds, synthetic compounds are 
more preferable and suitable to develop medicines for oral administration. This has 
motivated pharmaceutical companies to explore new small-molecule drug candidates 
through HTS screening systems. One of the screening systems available is based on the 
protein-protein interaction for the discovery of cell cycle inhibitors (Osada, 2009). 
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 Generally, most eukaryotic cell cycle progression is regulated by regulatory 
proteins. An unregulated cell cycle will lead to abnormal cell growth and thus, the 
occurrence of malignant cancers. Normal cells proliferate healthily in response to 
mitogenic signals, and on the other hand, the proliferation of cancer cells proceeds 
unchecked due to defects found in both the internal and external proliferation inhibitory 
signals as well as the negative-feedback systems (Nakayama and Nakayama, 2006). 
Therefore, insights in the fields of cell cycle regulation and cancer may provide a 
strategy in the development of novel therapeutic interventions (Frescas and Pagano, 
2008). 
It is well-known that in a normal cell cycle, a series of kinases control the cell 
cycle progression from one phase to another. In the cell cycle progression, the 
phosphorylation of proteins by the different members of the cyclin-dependent kinase 
(CDK) is crucial. The activation of CDK is dependent upon the association with a 
particular cyclin. Besides that, the activity of CDK is also controlled by the expression 
of the CDK inhibitors (CKIs). The ubiquitin-proteasome system (UPS) has an essential 
role in maintaining and regulating cellular homeostasis. This system controls the cellular 
abundance of a variety Cyclin/CDKs and CKIs of cellular proliferation which are known 
to be oncoproteins or tumour suppressors. Hence, these two types of post-translational-
protein modification namely phosphorylation and ubiquitination regulate the cell cycle 
(Bloom and Pagano, 2003; Nakayama and Nakayama, 2006). 
The close link between deregulated cell cycle and cancer was initially discovered 
when findings showed that genes encoding retinoblastoma (Rb) and p53 tumor 
suppressor proteins that inhibit cell-cycle progression appeared to be frequently mutated 
or deleted in human cancers (Nakayama and Nakayama, 2006; Chu et al., 2008). 
 3 
Moreover, deregulated expression or lost of one of the important CKIs, p27
Kip1
 that is 
commonly found in many human cancers is also associated with poor prognosis (Bloom 
and Pagano, 2003). Unlike the aforementioned tumor suppressors, p27
Kip1
 is rarely 
mutated or deleted in human cancers but is usually degraded through enhanced 
proteolysis (Chu et al., 2008).  
Clinical findings indicated that p27
Kip1
 is targeted for degradation by SCF
Skp2
 
which is an ubiquitin ligase complex, that consequently resulted with an overexpression 
of the S-phase kinase-associated protein 2 (Skp2) in many human cancers (Nakayama 
and Nakayama, 2005). In addition, numerous studies also showed that Skp2 exhibits 
oncogenic activity (Hershko, 2008). Thus, the involvement of Skp2 in many aggressive 
cancers suggests that targeting this protein through ubiquitin-proteasome pathway to 
restore p27
Kip1
 levels are poised to advance the field of cancer biology. With chemical 
biology approach, this thesis attempts to target the protein-protein interaction by small 
molecule inhibitors as a fundamental approach for future cancer therapy.  
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1.2 Hypothesis and Aims of Thesis 
In UPS, the involvement of the F-box protein known as Skp2 in the degradation 
of p27
Kip1
 that promoted tumorigenesis in human has not been fully elucidated and is 
still being extensively studied in many ongoing researches. Although studies have 
shown that proteasome inhibitors act to stabilize p27
Kip1 
(Adams and Kauffman, 2004), 
however, the discovery of small molecule inhibitors for the degradation of p27
Kip1
 to 
prevent cancers may contribute to the development of a specific targeted drug that could 
prove to be more efficacious with lesser side effects. 
In view of the effort to identify specific small molecule inhibitors of p27
Kip1
 
degradation, several compounds have been reported by several groups with various 
biochemical studies on Skp2-dependent degradation of p27
Kip1
 by those compounds 
have been confirmed (Chen et al., 2008; Rico-Bautista et al., 2010). This thesis expands 
upon the studies on the discovery of novel small molecule inhibitors of p27
Kip1
 
degradation by developing a HTS system to facilitate the search of the inhibitors from a 
large library of compounds. Furthermore, the thesis attempts to study the mode of action 
of the identified inhibitors.  
The flow of this thesis is outlined in the following: 
 CHAPTER THREE describes the construction of a novel screening system by 
baculoviruses through the approach of phosphorylation-dependent protein-
protein interaction to identify small molecule inhibitors of p27
Kip1
 degradation. 
This chapter also reports on the importance of several proteins involved in the 
protein-protein interaction in a phosphorylation-dependent manner. Moreover, 
the efficiency of the screening system to be further employed in HTS was 
evaluated. 
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  Upon the construction of the baculovirus-based screening system, HTS for the 
inhibitors of p27
Kip1
 degradation was performed by exploring the large chemical 
library in RIKEN Natural Products Depository (NPDepo) as described in 
CHAPTER FOUR. In the same chapter, the confirmation of the inhibitors 
activity identified from HTS in affecting the protein-protein interaction was 
outlined by the in vitro beads pull-down assay.  
 After that, CHAPTER FIVE expands the study of the inhibitor’s mode of action 
in the in vitro p27
Kip1
 ubiquitination by SCF
Skp2
 E3 Ligase. The importance of 
the involvement of several enzymes or reagents in this assay was also examined 
in this chapter. 
 CHAPTER SIX highlights the study of the inhibitors in a cellular context. This 
chapter describes the effect of the inhibitors on p27
Kip1
 stabilization in cancer 
cells in the effort to restore the level of p27
Kip1 
in human cancer. 
 Lastly, CHAPTER SEVEN summarizes on the examination of the activity of 
the inhibitors on cancer, transformed and normal cell growth. Those activities 
exhibited by the inhibitors were compared to evaluate the selectivity of the 
inhibitors in the cells. Furthermore, the study of the inhibitor’s effect on cell 
cycle progression was also included in this chapter.  
 
Specific aims of this thesis were: 
1. To construct a screening system by baculovirus protein expression system for the 
identification of small molecule inhibitors of p27
Kip1
 degradation.  
 6 
2. To screen for the inhibitors of p27Kip1 degradation by HTS system in a 
phosphorylation-dependent protein-protein interaction manner and to confirm the 
inhibitory activity obtained by in vitro beads pull-down assay. 
3. To examine the effect of the small molecule inhibitors on SCFSkp2-mediated in 
vitro ubiquitination of p27
Kip1
. 
4. To examine the effect of small molecule inhibitors on p27Kip1 stabilization in 
cancer cells. 
5. To study the selectivity of the small molecule inhibitors on the growth of cancer, 
transformed and normal cells as well as their effect on cell cycle progression. 
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CHAPTER TWO 
Literature Review 
2.1 Cell Cycle and Cancer 
 Recent insights in the field of cell cycle regulation have provided a better 
understanding as a platform for cancer research. Both cell cycle regulation and cancer 
are known to be closely related. A dysfunctional cell cycle regulation will lead to 
abnormal cell proliferation and these are the fundamentals of cancer development. 
Therefore, the understanding in the molecular mechanism underlying the deregulation of 
cell cycle progression in cancer is important to study how normal cells become 
tumorigenic and how cancer treatments can be designed. 
 Cancer cells and normal cells differ from one another with a number of important 
alterations in cell physiology that include several acquired capabilities namely; evading 
apoptosis, self-sufficiency in growth signals, insensitivity to anti-growth signals, tissue 
invasion and metastasis, limitless replicative potential and sustained angiogenesis as 
depicted in Figure 2.1 (Hanahan and Weinberg, 2000). These acquired capabilities are 
found in most and perhaps all types of human tumours. Each of the physiological 
changes as aforementioned represents the break through of an anticancer defense 
mechanism erratic into cells and tissues (Hanahan and Weinberg, 2000).   
Other than that, it has long been interpreted and suggested that tumorigenesis 
increased accordingly with age due to the gain of mutations and epigenetic abnormalities 
in the expression of multiple genes with highly diverse functions (Hanahan and 
Weinberg, 2000; Park and Lee, 2003). These important groups of genes were thought to 
involve in the cell cycle checkpoints (Park and Lee, 2003).  
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Figure 2.1 Capabilities acquired by most of the cancer cells 
 
Six acquired capabilities shown by most of the human cancers (Hanahan and Weinberg, 
2000). 
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Cell cycle progression is a highly-ordered and a tightly-regulated process with 
multiple checkpoints. These checkpoints are essential in the cell cycle machinery to 
sense flaws in important events such as DNA replication as well as to assess 
extracellular growth signals and cell size (Park and Lee, 2003). Figure 2.2 shows the 
somatic cell cycle which is divided into four phases namely G1, S, G2 and M phase.  
In each cell cycle, chromosomes are replicated once during the S-phase, followed 
by segregation of the chromosomes thereafter to generate two genetically identical 
daughter cells during the M-phase. These events are spaced by 2 gap phases; G1 and G2 
phase where the cells prepare for the successful completion of the S-phase and M-phase 
respectively.  
When cells stop cycling after division because of the presence or absence of a 
certain antimitogenic signals, cells enter a state of quiescence (G0) which is a non-
dividing state. Cells may also be arrested at G1 or G2 checkpoints for the evaluation on 
cell size, extracellular growth signals as well as the DNA integrity (Park and Lee, 2003). 
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Figure 2.2 A schematic representation of the somatic cell cycle 
 
The cell cycle is divided into four distinct phases: i) initial growth (G1-phase), ii) DNA 
synthesis (S-phase), iii) a gap/interval (G2-phase), and iv) mitosis (M-phase). The 
restriction point is the critical point of the cell cycle control where the cell cycle is 
irreversibly progressing to the next cell division (Park and Lee, 2003).  
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A proper maintenance of the cell cycle through its regulator is essential to 
prevent human cancers. This is because in a majority of human tumours, cell cycle 
regulators are commonly found to be mutated. Recently, abnormalities or mutations in 
Cyclins, CDKs and CKIs have frequently been associated with the process of tumour 
progression in human cancers (Sgambato et al., 1998). However, to understand the 
causes of mutations or abnormalities of the cell cycle regulatory proteins which have 
eventually led to the occurrence of many human cancers, studying and understanding the 
basic knowledge on the normal cell cycle is important and required (Park and Lee, 2003). 
Basically, the cell cycle control mechanism from G1 to M phase has been 
previously elucidated by several groups (Pardee, 1989; Morgan, 1995; Hwang and 
Muschel, 1998). According to their studies, the cell cycle progression involved a highly 
regulated kinase family known as the Cyclin-Dependent Kinases (CDKs). Kinase 
activation generally requires the association with another protein called cyclin, to create 
an active complex (Pardee, 1989; Morgan, 1995; Hwang and Muschel, 1998). Table 2.1 
and Figure 2.2 show the complexes formed between the CDKs and cyclins, as well as 
their involvements in cell cycle regulation. 
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Table 2.1 CDK-cyclin complexes 
 
 
Cyclins CDKs 
Cyclin A and B Cdc2 
Cyclin A, E and D Cdk2 
Cyclin D1, D2, D3 Cdk4, Cdk6 
Cyclin E Cdk3 
Cyclin C Cdk8 
Cyclin H Cdk7 
Cyclin T Cdk9 
p35 Cdk5 
Active complexes formed between mammalian CDKs and their regulatory cyclins (Park 
and Lee, 2003). 
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 CDKs and their cyclin partners are known to be the positive regulators of the cell 
cycle. They act as an accelerator in inducing the cell cycle progression. Contradictorily, 
the negative regulators of the cell cycle for example the inhibitors of the cyclin-
dependent kinase (CKIs) (Sherr and Roberts, 1995; Sherr and Roberts, 1999), act in an 
opposite manner. They act to halt the cell cycle progression depending on the regulatory 
signals.  
There are two families of CKIs which have been characterized namely; the Ink4 
family and the Kip/Cip family. Members of the Ink4 family which include p15
Ink4b
, 
p16
Ink4a
, p18 and p19 inhibit the progression of the cell cycle by binding to either CDK4 
or CDK6 and blocking the action of cyclin D. On the other hand, the members of 
Kip/Cip family of CKIs which include p21
Cip1
, p27
Kip1
 and p57
Kip2
 inhibit specifically 
the activity of CDK2 by binding to both complexes of CDK2/Cyclin E and 
CDK2/Cyclin A (Park and Lee, 2003). 
Therefore, controlling the regulation of these positive and negative regulators of 
the cell cycle is crucial as a major role in determining a proper progression of a cell 
cycle in order to avoid uncontrollable and abnormal proliferation of cells which are 
known to induce the occurrence of cancer. Recently, many works have been done to 
investigate the role of CKIs and meanwhile, this thesis focuses on one of the CKIs, 
p27
Kip1
 which is usually found to be deregulated in a majority of human cancers. 
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2.2 Cell Cycle Functions and Regulation of p27
Kip1
 
It is known that the control of eukaryotic cell cycle progression is governed by 
the cyclin dependent kinases (CDKs) which is activated upon cyclin binding and 
inhibited by the CDK inhibitors (CKIs) (Morgan, 1995; Sherr and Roberts, 1995; Sherr 
and Roberts, 1999; Chu et al., 2008). One of the CKIs, p27
Kip1
, which is a 198 amino 
acid protein that was originally discovered in cells arrested by transforming growth 
factor-β (TGF-β), by lovostatin and contact inhibition, (Polyak et al., 1994; Slingerland 
et al., 1994) has pivotal roles in the control of cell proliferation, cell motility, senescence 
and apoptosis (Sherr and Roberts, 1995; Sherr and Roberts, 1999; Chu et al., 2008). In 
the cell cycle, a p27
Kip1
 level is found to be high in G0 and early G1 to target inhibition 
on the G1 CDK/Cyclin primarily on the E-type cyclin/CDK2 complexes that eventually 
causes G1 cell cycle arrest.  
Studies have shown that a variety of abnormalities were observed in the p27
Kip1
 
knockout mice. When compare to the control animals, it was observed that mice lacking 
p27
Kip1 
developed multi organ enlargement that eventually led to an increase in the body 
size, multi organ hyperplasia, retina dysplasia and pituitary tumours (Slingerland and 
Pagano, 2000). These observations hence supported the importance of p27
Kip1
 in cell 
proliferation and differentiation (Fero et al., 1996; Nakayama et al., 1996).   
 Although the levels of p27
Kip1
 oscillate during the cell cycle, being at the highest 
level during G1, such a fluctuation in protein levels during the cell cycle is not similarly 
observed in the p27
Kip1
 mRNA levels. It has been reported that the mRNA levels of 
p27
Kip1 
remained constant throughout the cell cycle (Hengst and Reed, 1996). Instead, 
the p27
Kip1
 protein levels are known to be mainly regulated by a sequential degradation 
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system known as the ubiquitin-mediated proteolysis system (Pagano et al., 1995; Bloom 
and Pagano, 2003) which will be described in detail in the following section of 2.3.2.  
The functional inactivation of p27
Kip1
 can occur in several ways by the activation 
of tumour-associated oncogenes. For example, the overexpression of c-myc can induce a 
heat-labile factor that binds p27
Kip1
 and inhibits the association of p27
Kip1 
with 
CDK2/Cyclin E (Vlach et al., 1996). This effect is said to be independent of p27
Kip1
 
degradation. In certain cell types, it is reported that the upregulation of Cyclin D1 and 
D2 by c-myc leads to sequestration and inactivation of p27
Kip1
 (Slingerland and Pagano, 
2000).   
Other than that, several factors have been shown to cause the loss of p27
Kip1
 
(Slingerland and Pagano, 2000). Ras is one of the important factors reported for the loss 
of p27
Kip1
. According to Aktas et al. (1997) and Takuwa and Takuwa (1997), p27
Kip1 
accumulation and G1 cell cycle arrest were observed in the fibroblast cells transfected 
with a dominant negative ras allele. This suggests that for the progression of cell cycle 
from G1 to S phase, ras is required for the degradation of p27
Kip1
.  
However, another study has shown that ras itself is not sufficient for the loss of 
p27
Kip1
 but rather requiring co-expression of ras and myc (Leone et al., 1997). 
Furthermore, overexpression of mitogen-activated protein kinase (MAPK) in fibroblast 
has been reported to cause an increase in p27
Kip1
 degradation (Kawada et al., 1997).  
In contrast, these effects of ras on the loss of p27
Kip1
 have also been shown to be 
antagonized by the action of several chemicals (Slingerland and Pagano, 2000). For 
instance, effect of ras on p27
Kip1
 was abolished by the inhibitor of mitogen-activated 
protein kinase, PD9859 (Kawada et al., 1997). Other studies as reported in the previous 
publications by several groups also showed the effect of ras to be abrogated by 
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wortmannin (Ui et al., 1995) and LY294002 (Vlahos et al., 1994), which are the PI3K 
inhibitors. 
Generally, p27
Kip1
 is a phosphoprotein and the phosphorylation of p27
Kip1
 is 
known to be cell cycle regulated. Very commonly, phosphorylation of p27
Kip1
 is the 
signal for ubiquitination which is the process responsible for the degradation of p27
Kip1
 
(Alessandrini et al., 1997). The regulation of p27
Kip1
 degradation is related to its 
phosphorylation by Cyclin E/CDK2 complex (Sheaff et al., 1997; Vlach et al., 1997 
Montagnoli et al., 1999; Slingerland and Pagano, 2000). Therefore, understanding the 
pathways or mechanisms that trigger the phosphorylation of p27
Kip1
 followed by the 
degradation meachanisms may provide mechanistic links for further evaluation between 
the deregulated cell cycle in cancers and the activation of oncogenes and tumor 
suppressors (Slingerland and Pagano, 2000).  
 
2.3 The Ubiquitin-Proteasome System (UPS) 
 About more than three decades ago, it has been reported that many regulatory 
proteins indeed have a short life and a majority of them are degraded through the 
ubiquitin proteasome pathway (Schimke, 1973). Therefore, the ubiquitin-proteasome 
pathway is the principal mechanism and selective degradation of various short-lived 
proteins in eukaryotic cells (Pickart, 1997; Hershko and Ciechanover, 1998). This 
pathway controls the degradation of a vast majority of proto-oncogenes, tumour 
suppressors as well as the components responsible for the signal transduction system 
which determine the cell growth and the cell proliferation. Because of that, 
abnormalities or dysfunctional ubiquitin-mediated processes will eventually cause 
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pathological conditions including malignant transformation (Hershko and Ciechanover, 
1998). 
 In UPS, degradation of a particular targeted protein occurred through covalent 
ligation to ubiquitin, which is a 76 amino acid residue protein. Ubiquitin acts as a 
degradative tag of the targeted proteins upon the recognition of the targeted proteins by 
the 26S proteasome for degradation. Together, the function of ubiquitin as a covalent 
degradation signal and the properties of the 26S proteasome as an enzyme created novel 
features of UPS (Pickart, 1997). 
The overview of UPS is illustrated in Figure 2.3. Briefly, a targeted protein is 
degraded through a sequential degradation system, requiring the action of three enzymes. 
Step one of the UPS begins with the activation of the entire cellular pool of the ubiquitin 
molecules at the C-Terminal Gly residue in an ATP-dependent manner by a specific 
activating enzyme called E1. This step involves the binding of the ubiquitin molecule to 
a Cys residue to E1 through thiolester linkage, releasing AMP.  
Then, step two of the UPS continues the system with the ubiquitin-conjugating 
enzyme known as E2, to inherit the activated thiolester-bonded ubiquitin from the E1 
enzyme. After that in the third step of this system, the E3 ligase enzyme binds both the 
target substrate and the E2 complex which then transfers ubiquitin to the target protein. 
This step features the selectivity of protein degradation which is determined by the 
specificity of a certain class of cellular proteins that bind to a specific E3 ligase enzyme. 
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Figure 2.3 Schematic representation of the ubiquitin-proteasome pathway 
 
The pathway begins with the transferring of ubiquitin (Ub) protein in an ATP-dependent 
manner to the ubiquitin-activating enzyme (E1). The activated ubiquitin is then 
transferred to the ubiquitin-conjugating enzyme (E2), followed by the covalent 
attachment of ubiquitin to the target protein by the ubiquitin ligase (E3), forming a 
polyubiquitin chain. Upon polyubiquitination of the target protein, the polyubiquitinated 
protein is recognized by the 26S proteasome and degraded (Nakayama and Nakayama, 
2006). 
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Several rounds of the ubiquitin conjugation produce polyubiquitination (long 
chains of ubiquitin moieties) of the target protein. The polyubiquitinated target protein 
will then be recognized by the 26S proteasome prior to its degradation. The ubiquitin 
molecules are then freed and released upon the degradation of the target protein  
(Hershko and Ciechanover, 1998; Nakayama and Nakayama, 2006). 
Studies have also shown that there is only a single E1 but multiple species of E2 
and E3 which involve in the ligation to ubiquitin of different proteins (Hershko and 
Ciechanover, 1998). As the specificity of an ubiquitin system is determined by the E3 
ligase enzyme, therefore majority of the studies on UPS concentrated on the E3 
ubiquitin ligases (Nakayama and Nakayama, 2005). 
 Generally, the E3 ubiquitin ligases are categorized into four classes; RING-
finger type, HECT-type, U-box-type and PHD-finger-type. The RING-finger-type E3 
ligases are further divided into subfamilies including the cullin-based E3 ligase. In fact, 
there are seven cullin-based E3 ligases as shown in Figure 2.3 (Nakayama and 
Nakayama, 2006). Two major cullin-based E3 ligases which have a central role in cell-
cycle regulation are the Skp1-Cul1-F-box-protein (SCF) complex and the anaphase-
promoting complex/cyclosome (APC/C) (Nakayama and Nakayama, 2006). This thesis 
involves the examination on the degradation of one of the CKIs, p27
Kip1
 through 
ubiquitination by the SCF complex with Skp2 as the specific F-box protein. 
. 
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2.3.1 SCF and F-Box Protein (FBP)  
 In UPS, E3 components are primarily responsible for the specific recognition of 
target proteins (Hershko, 1983). Referring to Figure 2.3 in the previous section, E3 
ligases are divided into four major classes according to their specific structural motif, in 
which RING-finger-type E3 ligases appeared to be the largest family with subfamilies. 
Cullin-based E3 subfamily, for example the Skp1-Cul1-F-box-protein (SCF) complex is 
involved in the proteolysis of the components of the cell-cycle machinery (Nakayama 
and Nakayama, 2006).  
In this complex, Cul1 (Cullin subunit) functions as a molecular scaffold protein 
that interacts simultaneously with an adaptor protein, Skp1 (S-phase kinase-associated 
protein 1) at the amino-terminus, and while at the carboxyl-terminus, it interacts with a 
RING-finger protein called Rbx1 which is also known as Roc1 or Roc2 (Cardozo and 
Pagano, 2004).  
 Skp1 binds to one of the many F-box-proteins (FBPs) and was thought to be 
important for the ubiquitin-mediated proteolysis of the Cdk inhibitor, Sic1. It was 
discovered that Skp1 was able to bind to many protein for example cyclin F and Cdc4 
through a conserved 40-amino-acid domain. Since Skp1 was first noted in cyclin F, 
hence this has led to the introduction of the F-box family of proteins. Therefore, cyclin F 
and Cdc4 were known as the first F-box proteins identified (Bai et al., 1996). Following 
that, further studies have found that Sic1 ubiquitination involved an E3 ligase which is 
formed by Cul1, Skp1 and Cdc4. Thus, this complex was later called as the SCF 
ubiquitin ligase (Feldman et al., 1997; Skowyra et al., 1997; Cardozo and Pagano, 2004). 
 The SCF complex is constituted of common subunits and a variable substrate-
recognition subunit known as the FBPs. Three FBPs in the SCF complex which 
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appeared to be the most important key players in cell cycle regulation are the S-phase 
kinase-associated protein 2 (Skp2), F-box and WD-40 domain protein 7 (FBW7) and β-
transducin repeat-containing protein (β-TRCP). These FBPs target known substrates, 
implicating their functions in the control of the cellular proliferation. On the other hand, 
the functions of most of the other F-box proteins are still preliminary or remained 
unknown (Cardozo and Pagano, 2004; Nakayama and Nakayama, 2006). 
 Skp2 is known to target the negative regulators of the cell-cycle namely, p27
Kip1
, 
p21
Cip1
 and p57
Kip2
 for degradation, promoting cell cycle progression from G1 to S phase. 
Because of uncontrolled cell proliferation, hence Skp2 level is frequently found to be 
upregulated in a majority of human cancers. Another example of FPBs which is FBW7 
is often found to be mutated in a subset of human cancers. FBW7 on the other hand, 
targets the positive regulators of the cell cycle such as MYC, JUN, cyclin E and Notch 
for degradation. Whereas for β-TRCP, it targets β-catenin and IκB as well as recognizes 
a number of cell cycle regulators for instance; EMI1/2, WEE1A and CDC25A/B for 
degradation (Nakayama and Nakayama, 2006).  
Based on the fact that the expression level of Skp2 is usually found to be 
inversely correlated to that of p27
Kip1
 (a tumour suppressor) with overexpression of Skp2 
and deregulation of p27
Kip1
 commonly observed in human tumours, hence Skp2 is 
proven to act as an oncogene. The involvement of Skp2 in promoting tumorigenesis 
therefore requires the development of small molecule inhibitors against the interaction of 
Skp2 and p27
Kip1 
as the fundamental approach for future cancer therapeutics (Frescas 
and Pagano, 2008).  
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2.3.2 Regulation of p27
Kip1
 by the Ubiquitin-Proteasome System (UPS) 
 Unlike other tumor suppressors proteins for example p53, p27
Kip1
 is rarely 
mutated in human cancers but is usually deregulated in cancers even in the presence of 
high or constant p27
Kip1
 mRNA levels (Catzavelos et al., 1997; Slingerland and Pagano, 
2000; Chu et al., 2008). In cell cycle, p27
Kip1
 negatively regulates G1 to S phase 
transition, and its levels are found to be highest at G1 phase causing G1 cell cycle arrest 
(Sherr and Roberts, 1995; Coats et al., 1996; Hengst and Reed, 1996; Chu et al., 2008). 
However, such a fluctuation in protein levels during the cell cycle is not similarly 
observed in the p27
Kip1
 mRNA levels (Hengst and Reed, 1996; Alessandrini et al., 1997). 
Thus, this suggests that down-regulation of p27
Kip1
 in human cancers which is associated 
with many aggressive phenotypes and a poor prognosis in a variety of cancers (eg. breast, 
colon, prostate, lung and gastric cancers) is mainly due to post transcriptional events 
rather than by transcription (Hengst and Reed, 1996; Chu et al., 2008). 
The cell cycle levels of Skp2 and p27
Kip1
 are known to be inversely correlated to 
each other. In the early/mid G1 of the cell cycle, the level of Skp2 expression is low 
while the level of p27
Kip1
 is high. When the cell cycle reaches the late G1 phase, an 
inverse effect occurs whereby the expression of Skp2 increases in contrast to a decrease 
in p27
Kip1
 levels (Slingerland and Pagano, 2000). 
 It is known that p27
Kip1
 is degraded through a sequential degradation system 
called the ubiquitin-proteasome system (UPS) (Pagano et al., 1995). This system begins 
with the small ubiquitin protein being transferred and covalently attached to the target 
proteins by a cascade of enzymatic reaction followed by degradation of the marked 
target proteins by proteasome as described in the previous section (Hershko and 
Ciechanover, 1998).  
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Biochemical studies have shown that p27
Kip1
 is ubiquinated and degraded in vitro 
and in vivo mainly by the SCF-type (Skp1-Cullin-F-box protein) ubiquitin ligase 
complex that contains S-phase kinase-associated protein 2 (Skp2) as the specific 
substrate-recognition subunit (SCF
Skp2
) (Carrano et al., 1999; Sutterluty et al., 1999; 
Tsvetkov et al., 1999; Nakayama et al., 2000). The mechanism of degradation of p27
Kip1
 
through UPS by SCF
Skp2
 is illustrated in Figure 2.4.  
As shown in Figure 2.4, p27
Kip1 
is recognized by Skp2 only when it is 
phosphorylated by cyclinE/Cdk2 on Threonine-187 (T-187) (Sheaff et al., 1997; Vlach 
et al., 1997; Montagnoli et al., 1999). Moreover, recognition of p27
Kip1
 by SCF
Skp2
 also 
requires an accessory protein, CDK subunit 1 (Cks1) that binds to both Skp2 and 
phosphorylated p27
Kip1 
(Ganoth et al., 2001; Spruck et al., 2001). After the recognition 
of p27
Kip1
 by Skp2 and Cks1, the mechanism is then followed by the stimulation of 
p27
Kip1
 targeting for ubiquitination by the SCF
Skp2
 complex. The ubiquitinated p27
Kip1
 is 
then rapidly destroyed by the proteasome, thus releasing active cyclinE/Cdk2 and 
allowing the progression of the cell cycle to S-phase (Hershko, 2008). 
In conclusion, p27
Kip1
 proteolysis is regulated in response to the cooperation of a 
number of events initiated by a mitogenic stimulus. For example, the increase in the 
levels of cyclin E, Skp2 and Cks1 has resulted in the p27
Kip1
 phosphorylation and 
degradation. Although the function of p27
Kip1 
is rarely disrupted at the genetic level, 
however the enhanced ubiquitin-mediated proteolysis that caused the rapid degradation 
of p27
Kip1
 has promoted various human malignancies (Slingerland and Pagano, 2000). 
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Figure 2.4 Mechanism of p27
Kip1 
degradation by SCF
Skp2
 complex 
 
The Cdk/cyclin complex as shown in this figure is the Cdk2/cyclin E complex. After the 
phosphorylation of p27
Kip1 
by Cdk2/cyclin E at T187, p27
Kip1
 is then recognized by Skp2 
and Cks1 which triggers the ubiquitination of p27
Kip1 
by the SCF
Skp2
 complex. The 
ubiquitinated p27
Kip1
 eventually undergo proteolysis by the proteasome, thus allowing 
the release of active Cdk2/cyclin E and progression to the S-phase (Hershko, 2008).  
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